Value Sense
POAI
Predictive Oncology Inc. (POAI)
Last Price$1.3(9.4%)
Market Cap$8,155.2K
Intrinsic value score
4/10
Good
Intrinsic value
$5.0
DCF value - N/A Relative value - $5.0
Undervalued
297.3%
LTM P/E
(0.6x)
Peer set median 31.0x
Discount rate
7.3%
POAI
is 297.3% undervalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

POAI Intrinsic value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 03, 2025 POAI Relative Value is $5.1, which is undervalued by 301.8%, compared to current share price of $1.3.
DCF Value vs Current Share Price
As of Mar 03, 2025 POAI DCF Value is N/A, which is undervalued by N/A, compared to current share price of $1.3.
Methodology
Price per share, $
POAI
Intrinsic value$5.0
Undervalued by297.3%
Current share price
1.3
Relative value
5.1
DCF value
not available

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

POAI Historical Intrinsic Value

Crunching data... Almost there!

POAI vs Peer Set: Intrinsic Value Comparison

General

Intrinsic Value

Financials

Company name

Undervaluation/Overvaluation

Revenue growth

EPS growth

Net income margin

Predictive Oncology Inc. logo
Predictive Oncology Inc.POAI
297.3%
18.2%
(64.9%)
(785.6%)
Median Peer Set
3.4%
23.0%
10.4%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
(81.3%)
17.2%
27.7%
27.8%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
(33.0%)
(1.9%)
(15.5%)
17.0%
Masimo Corporation logo
Masimo CorporationMASI
(26.6%)
0.6%
(42.5%)
4.0%
ResMed Inc. logo
ResMed Inc.RMD
(18.2%)
10.9%
13.4%
21.8%
Alcon Inc. logo
Alcon Inc.ALC
(13.6%)
8.5%
182.9%
10.3%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
1.2%
8.4%
32.2%
10.1%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
15.0%
4.2%
18.3%
8.4%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
19.0%
2.7%
30.2%
10.5%
Baxter International Inc. logo
Baxter International Inc.BAX
51.1%
(69.5%)
(100.0%)
(6.9%)
Hologic, Inc. logo
Hologic, Inc.HOLX
108.2%
(0.0%)
81.1%
19.6%

Explore more intrinsic value tools hub for POAI

DCF value calculator
Reverse DCF
Peter Lynch charts
Relative Value
Earnings growth model
Peter Lynch Fair Value
Margin of safety
Ben Graham Fair Value
Earnings Power Value
Discount rate

FAQ

What is Predictive Oncology Inc. intrinsic value?

As of Mar 03, 2025, Predictive Oncology Inc. Intrinsic Value is $5.0. This suggests it may be undervalued by 297.3% compared to its current price of around $1.3.

What is Predictive Oncology Inc. DCF (discounted cash flow) valuation?

As of Mar 03, 2025, Predictive Oncology Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $1.3, using a discount rate of 7.3% and terminal growth rate of 3.0%.

Is Predictive Oncology Inc. overvalued or undervalued?

Predictive Oncology Inc. is currently considered undervalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $5.0, compared to a market price of around $1.3. This suggests a potential undervaluation of 297.3%.